Mirati Therapeutics, Inc.
MRTXDelisted Jan 23, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001576263
Mirati Therapeutics, Inc. was delisted on Jan 23, 2024; its insiders filed their last Form 4 on Jan 25, 2024; 218 institutions reported holding it in 13F filings for Q4 2023, worth $4.66B in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 218
- Q4 2023, +5 vs. previous quarter
- 13F value
- $4.66B
- Reported value at the end of Q4 2023
- Superinvestors holding
- 0
- At the end of Q4 2023
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2022
- $12.4M
- −82.7% year over year
- Net income, FY2022
- -$740.9M
- No comparable prior period
- Free cash flow, FY2022
- -$575.4M
- No comparable prior period
- Revenue, Q3 FY2023
- $16.4M
- +202.0% year over year
Revenue flow, FY2022
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2022: $740.9M (5957.4% of revenue).
Superinvestors holding MRTX, Q4 2023
Go to the superinvestors tabNo superinvestor reported holding MRTX at the end of Q4 2023.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Mirati Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Hickey BenjaminEVP, Chief Commercial Officer | SSale | −1.60K | $59.02 | −$94.3K | −1.3%117.0K after | 2 lots |
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Christensen JamieEVP & Chief Scientific Officer | SSale | −1.60K | $59.02 | −$94.3K | −1.0%155.9K after | 2 lots |
| Jan 9, 2024 (view filing) | Jan 8 | 1 day | Hickey BenjaminEVP, Chief Commercial Officer | SSale | −2.09K | $58.92 | −$123.1K | −1.7%118.6K after | |
| Jan 5, 2024 (view filing) | Jan 4 | 1 day | Christensen JamieEVP & Chief Scientific Officer | SSale | −1.53K | $58.81 | −$90.0K | −1.0%157.1K after | |
| Dec 19, 2023 (view filing) | Dec 18 | 1 day | Christensen JamieEVP & Chief Scientific Officer | SSale | −2.39K | $57.50 | −$137.3K | −1.7%141.6K after | |
| Dec 14, 2023 (view filing) | Dec 13 | 1 day | Hickey BenjaminEVP, Chief Commercial Officer | SSale | −2.22K | $56.67 | −$125.8K | −2.1%103.7K after | |
| Sep 12, 2023 (view filing) | Sep 8 | 4 days | Christensen JamieEVP & Chief Scientific Officer | SSale | −2.39K | $35.63 | −$85.1K | −1.6%144.0K after | |
| Aug 15, 2023 (view filing)9:39 PM ET | Aug 11 | 4 days | Lewis Joseph and 6 othersOther: See remarks | PPurchase | +57.5K | $27.80 | +$1.60M | +25.0%287.9K after | Duplicate filing |
| Aug 15, 2023 (view filing)9:39 PM ET | Aug 11 | 4 days | Lewis Joseph and 6 othersOther: See remarks | PPurchase | +1.20M | $27.80 | +$33.4M | +60.1%3.20M after | Duplicate filing |
| Aug 15, 2023 (view filing)9:38 PM ET | Aug 11 | 4 days | Lewis Joseph and 6 othersOther: See remarks | PPurchase | +57.5K | $27.80 | +$1.60M | +25.0%287.9K after |
Top 10 13F holders, Q4 2023
See all 218 holdersThe largest institutional positions in Mirati Therapeutics, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 7,396,979 | $434.6M | 11.29% | +1,648,580+28.7% | Added |
| RTW Investments, LP | 6,768,514 | $397.7M | 6.21% | 00.0% | Unchanged |
| Morgan Stanley | 6,169,382 | $362.5M | 0.03% | +3,707,250+150.6% | Added |
| Vanguard Group Inc | 5,306,693 | $311.8M | 0.01% | −392,939−6.9% | Reduced |
| Avoro Capital Advisors LLC | 4,886,840 | $287.1M | 3.97% | −1,779,826−26.7% | Reduced |
| Baker Bros. Advisors LP | 4,121,440 | $242.1M | 2.76% | +2,711,656+192.3% | Added |
| BlackRock Inc. | 3,866,202 | $227.1M | 0.01% | +321,891+9.1% | Added |
| Boxer Capital, LLC | 3,201,440 | $188.1M | 9.37% | 00.0% | Unchanged |
| Sawtooth Solutions, LLC | 3,135,973 | $184.2M | 5.03% | +3,135,973 | New |
| Braslyn Ltd. | 3,135,966 | $184.2M | 98.96% | +3,135,966 | New |
Politician trades
All politician trades in MRTX1 member of Congress reported 2 trades in Mirati Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| May 19, 2023 |  Daniel S. Goldman House · NY | Sell | $1K-$15K |
| Apr 17, 2023 | Daniel S. Goldman House · NY | Buy | $1K-$15K |
House · NY · May 19, 2023
Sell$1K-$15K
House · NY · Apr 17, 2023
Buy$1K-$15K